JP2004517810A - 片頭痛の処置のためのプロポフォールの水溶性プロドラッグ - Google Patents

片頭痛の処置のためのプロポフォールの水溶性プロドラッグ Download PDF

Info

Publication number
JP2004517810A
JP2004517810A JP2002518956A JP2002518956A JP2004517810A JP 2004517810 A JP2004517810 A JP 2004517810A JP 2002518956 A JP2002518956 A JP 2002518956A JP 2002518956 A JP2002518956 A JP 2002518956A JP 2004517810 A JP2004517810 A JP 2004517810A
Authority
JP
Japan
Prior art keywords
propofol
migraine
pharmaceutically acceptable
water
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002518956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517810A5 (enExample
Inventor
エス． ヘンドラー，シェルドン
Original Assignee
バイレックス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイレックス コーポレイション filed Critical バイレックス コーポレイション
Publication of JP2004517810A publication Critical patent/JP2004517810A/ja
Publication of JP2004517810A5 publication Critical patent/JP2004517810A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002518956A 2000-08-15 2001-08-14 片頭痛の処置のためのプロポフォールの水溶性プロドラッグ Pending JP2004517810A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/639,015 US6362234B1 (en) 2000-08-15 2000-08-15 Water-soluble prodrugs of propofol for treatment of migrane
PCT/US2001/025540 WO2002013810A1 (en) 2000-08-15 2001-08-14 Water-soluble prodrugs of propofol for treatment of migraine

Publications (2)

Publication Number Publication Date
JP2004517810A true JP2004517810A (ja) 2004-06-17
JP2004517810A5 JP2004517810A5 (enExample) 2008-10-02

Family

ID=24562380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002518956A Pending JP2004517810A (ja) 2000-08-15 2001-08-14 片頭痛の処置のためのプロポフォールの水溶性プロドラッグ

Country Status (5)

Country Link
US (1) US6362234B1 (enExample)
EP (1) EP1318798A4 (enExample)
JP (1) JP2004517810A (enExample)
CA (1) CA2419047A1 (enExample)
WO (1) WO2002013810A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011173999A (ja) * 2010-02-25 2011-09-08 Shin-Etsu Chemical Co Ltd リン酸エステル基含有オルガノポリシロキサン及びその製造方法
JP2011195719A (ja) * 2010-03-19 2011-10-06 Shin-Etsu Chemical Co Ltd リン酸エステル基含有オルガノポリシロキサンの製造方法

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
BR0215303A (pt) * 2001-12-28 2005-04-05 Guilford Pharm Inc Formulações farmacêuticas de base aquosa de pró-drogas solúveis em água de propofol
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CA2480881C (en) * 2002-04-08 2012-09-11 Guilford Pharmaceuticals, Inc. Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
DE20215415U1 (de) * 2002-10-08 2004-02-26 Biotechnologie Gesellschaft Mittelhessen Mbh Wasserlösliche Medikamentenvorstufen von Propofol
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
ZA200504940B (en) * 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US7230003B2 (en) * 2003-09-09 2007-06-12 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
EP1680409A4 (en) * 2003-10-24 2007-12-05 Auspex Pharmaceuticals Inc PH-SENSITIVE 2,6-DIISOPROPYLPHENOL PROMEDICAMENTS
CA2548216A1 (en) * 2003-12-17 2005-06-30 Mgi Gp, Inc. Methods of administering water-soluble prodrugs of propofol for extended sedation
ES2315897T3 (es) * 2004-07-12 2009-04-01 Xenoport, Inc. Aminoacidos derivados de porfarmacos de composiciones de propofol y usos del mismo.
WO2006017351A1 (en) * 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
US20080214508A1 (en) * 2004-09-17 2008-09-04 Mgi Gp, Inc. Methods of Administering Water-Soluble Prodrugs of Propofol
DE602005019210D1 (de) * 2004-12-23 2010-03-18 Xenoport Inc Von serinaminosäure abgeleitete prodrugs von propofol, zusammensetzungen, anwendungen und kristalline formen davon
EP1893159B1 (en) 2005-06-17 2015-09-30 Vital Health Sciences Pty Ltd. A carrier comprising one or more di- and/or monophosphate derivatives of electron transfer agents
US20080234229A1 (en) * 2005-08-18 2008-09-25 Auspex Pharmaceuticals, Inc. Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
US7589239B2 (en) * 2005-09-02 2009-09-15 Auspex Pharmaceuticals Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
EP2810927A1 (en) 2007-05-09 2014-12-10 Sowood Healthcare LLC Therapeutic compounds
KR20100017435A (ko) 2007-05-09 2010-02-16 파마코포어, 인크. 치료 화합물
WO2008157627A1 (en) * 2007-06-21 2008-12-24 Xenoport, Inc. Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
US20090076141A1 (en) * 2007-09-14 2009-03-19 Xenoport, Inc. Use of Propofol Prodrugs for Treating Neuropathic Pain
GB0905834D0 (en) 2009-04-03 2009-05-20 Seps Pharma Nv Phosphonyl-containing phenolic derivatives useful as medicaments
CN101575349B (zh) * 2009-06-11 2011-07-20 中国科学院广州化学研究所 一种丙泊酚磷酸酯二钠盐的制备方法
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
WO2011120084A1 (en) 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
WO2011161687A1 (en) 2010-06-23 2011-12-29 Harman Finochem Limited Process for preparing extra pure 2, 6-diisopropyl phenol
CN101885735B (zh) * 2010-06-23 2012-09-12 四川大学华西医院 取代苯酚羟基酸酯的磷酸酯化合物、制备方法及在药物中的应用
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
CN102260184B (zh) * 2011-06-09 2014-07-02 浙江九旭药业有限公司 丙泊酚衍生物及其制备方法和应用
ES2981002T3 (es) 2015-12-09 2024-10-04 Avecho Biotechnology Ltd Formulación farmacéutica
US11331271B2 (en) 2016-05-27 2022-05-17 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
AU2017381395A1 (en) 2016-12-21 2019-06-20 Phosphagenics Limited Process
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
WO2021078073A1 (zh) 2019-10-22 2021-04-29 四川大学华西医院 一类取代苯酚羟基酸酯含n衍生物、制备和用途
EP3912621A1 (en) * 2020-05-19 2021-11-24 tesa Labtec GmbH Propofol for diagnosis of primary headache

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058555A2 (en) * 1998-05-08 1999-11-18 Vyrex Corporation Water-soluble pro-drugs of 2,6-diisopropylphenol analogues

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
JPH08339002A (ja) * 1995-04-10 1996-12-24 Ngk Insulators Ltd 第二高調波発生素子およびその製造方法
US5891875A (en) * 1996-05-20 1999-04-06 Eli Lilly And Company Morpholinyl tachykinin receptor antagonists
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058555A2 (en) * 1998-05-08 1999-11-18 Vyrex Corporation Water-soluble pro-drugs of 2,6-diisopropylphenol analogues

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011173999A (ja) * 2010-02-25 2011-09-08 Shin-Etsu Chemical Co Ltd リン酸エステル基含有オルガノポリシロキサン及びその製造方法
JP2011195719A (ja) * 2010-03-19 2011-10-06 Shin-Etsu Chemical Co Ltd リン酸エステル基含有オルガノポリシロキサンの製造方法

Also Published As

Publication number Publication date
CA2419047A1 (en) 2002-02-21
WO2002013810A1 (en) 2002-02-21
EP1318798A4 (en) 2004-01-28
US6362234B1 (en) 2002-03-26
EP1318798A1 (en) 2003-06-18

Similar Documents

Publication Publication Date Title
JP2004517810A (ja) 片頭痛の処置のためのプロポフォールの水溶性プロドラッグ
US6254853B1 (en) Water soluble pro-drugs of propofol
JP3074733B2 (ja) 脂肪乳剤
US20130225529A1 (en) Phospho-ester derivatives and uses thereof
KR100400075B1 (ko) 세포로의침투가개선된약제
KR20080016621A (ko) 염증성 질병 치료용 조성물 및 방법
JPWO1991010431A1 (ja) 脂肪乳剤
CN100536851C (zh) 丙戊酸的磷脂衍生物及其混合物
JPH05213744A (ja) 炎症性疾患の処置のための薬剤調製物
JP3036881B2 (ja) ビロバリデ誘導体、この用途及びこれを含有する薬剤組成物
WO1999024400A1 (en) Probucol esters and uses thereof
PT1771155E (pt) Método e composição para o tratamento da rinite
EP0661053A1 (en) Use of tocopherol ascorbic adic phosphates for hemorrhoidal diseases
EP1140115B1 (en) Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
JP2003534298A (ja) 咳の新規治療法
KR20050085736A (ko) 에스테르 조합 국소마취제
KR950005914B1 (ko) Nmda-차단 제약조성물
JP2002524016A (ja) イノシトールポリホスフェート誘導体およびその使用方法
US20250064729A1 (en) Methods and formulations for improving the pharmacokinetic properties of nutraceutical compounds
US20240316073A1 (en) Cannabidiolic acid esters for treating prader-willi syndrome
WO2025054536A1 (en) Cannabinoid delivery
KR101198201B1 (ko) 비염 치료를 위한 방법 및 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120306